Skip to main content

Market Overview

Amathus Therapeutics, Merck In Agreement For Neurodegenerative Disease-Targeted Therapies


Privately-held Amathus Therapeutics has entered into a strategic collaboration with Merck & Co (NYSE: MRK) to develop novel small molecule therapeutic candidates for neurodegenerative diseases.

  • Under the terms of the agreement, Amathus will be responsible for identifying and progressing novel chaperone activators through preclinical discovery.
  • Merck has the option to acquire Amathus Therapeutics and its pipeline of mitochondrial-targeted candidates for the treatment of neurodegenerative disorders and renal diseases.
  • Amathus will receive an upfront payment from Merck. If Merck exercises its option, Amathus will be eligible for milestone payments associated with candidates' successful development above $500 million per program.
  • Price Action: MRK shares are down 0.35% at $76.54 on the last check Wednesday.

Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at